SKP.L Regulatory News (SKP)

17 May 2006 09:00

Skyepharma PLC17 May 2006 For Immediate Release 17 May 2006 SkyePharma PLC SkyePharma's Chief Operating Officer Appointed to Board LONDON, UK, 17 May 2006 - SkyePharma PLC (LSE: SKP; Nasdaq: SKYE) announces theappointment of Dr Ken Cunningham, Chief Operating Officer, as a Director of theCompany. It was announced in February that Dr Ken Cunningham, previously ChiefExecutive of the privately-owned UK biotechnology company Arakis, would becomeChief Operating Officer of SkyePharma and he took up this appointment on 24April. Dr Ken Cunningham said: "I am very pleased to join the Board of SkyePharma. Withthe ongoing divestment of our Injectables business, I will be focusing on themanagement of our core Oral and Inhalation products where I will apply myexperience in pharmaceutical development. I am impressed by SkyePharma'stechnical staff and see working with them to maximise the value of our pipelineproducts as a key part of my role at SkyePharma." Dr Jerry Karabelas, SkyePharma's Non-executive Chairman, said: "We welcome Kento the Board and look forward to gaining his input on operational and strategicdecisions." Shareholders will have the opportunity to confirm the appointment of DrCunningham as a Director at the next Annual General Meeting, which will be inJune 2006. For further information please contact: SkyePharma PLC Frank Condella, Chief Executive +44 207 491 1777 Peter Laing, Director of Corporate Communications +44 207 491 5124 Sandra Haughton, US Investor Relations +1 212 753 5780 Buchanan Communications +44 207 466 5000 Tim Anderson / Mark Court / Rebecca Skye Dietrich Notes for editors About SkyePharma SkyePharma PLC develops pharmaceutical products benefiting from world-leadingdrug delivery technologies that provide easier-to-use and more effective drugformulations. There are now twelve approved products incorporating SkyePharma'stechnologies in the areas of oral, injectable, inhaled and topical delivery,supported by advanced solubilisation capabilities. For more information, visitwww.skyepharma.com. Certain statements in this news release are forward-looking statements and aremade in reliance on the safe harbour provisions of the U.S. Private SecuritiesLitigation Act of 1995. Although SkyePharma believes that the expectationsreflected in these forward-looking statements are reasonable, it can give noassurance that these expectations will materialize. Because the expectations aresubject to risks and uncertainties, actual results may vary significantly fromthose expressed or implied by the forward-looking statements based upon a numberof factors, which are described in SkyePharma's 20-F and other documents on filewith the SEC. Factors that could cause differences between actual results andthose implied by the forward-looking statements contained in this news releaseinclude, without limitation, risks related to the development of new products,risks related to obtaining and maintaining regulatory approval for existing, newor expanded indications of existing and new products, risks related toSkyePharma's ability to manufacture products on a large scale or at all, risksrelated to SkyePharma's and its marketing partners' ability to market productson a large scale to maintain or expand market share in the face of changes incustomer requirements, competition and technological change, risks related toregulatory compliance, the risk of product liability claims, risks related tothe ownership and use of intellectual property, and risks related toSkyePharma's ability to manage growth. SkyePharma undertakes no obligation torevise or update any such forward-looking statement to reflect events orcircumstances after the date of this release. This information is provided by RNS The company news service from the London Stock Exchange